BCHT’s recombinant shingles vaccine clinical trial application approved

June 6, 2025  Source: drugdu 74

"/
On the evening of June 4, BCHT, the company announced that it had received the "Notice of Approval for Drug Clinical Trial" for the recombinant herpes zoster vaccine (CHO cells) issued by the National Medical Products Administration, and the conclusion was that it agreed to conduct clinical trials for the prevention of herpes zoster.


Herpes zoster is an acute infectious skin disease caused by the reactivation of the varicella-zoster virus (VZV) lurking in the body. The recombinant herpes zoster vaccine (CHO cells) approved for clinical use by Biotech is for adults aged 40 and above. After vaccination, it can stimulate the body to produce immunity against the varicella-zoster virus and is used to prevent herpes zoster.


According to reports, the recombinant shingles vaccine (CHO cells) developed by the company is based on varicella-zoster virus glycoprotein E (gE protein) and is combined with the company's independently developed innovative BK-02 adjuvant system. It can stimulate the body's immune system to produce high levels of gE protein-specific antibodies and cellular immune responses, and has strong immune persistence, thereby preventing skin herpes zoster and neuralgia caused by varicella-zoster virus.


Beike Bio said that if the vaccine variety successfully completes clinical trials and is approved for marketing, it will further enrich the company's shingles vaccine product portfolio, provide more diverse vaccination options for recipients, help the company optimize its product structure, industrial layout and the overall development of its main business, and enhance the company's long-term profitability.

https://finance.eastmoney.com/a/202506043422006637.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.